Chronic pancreatitis laboratory findings: Difference between revisions

Jump to navigation Jump to search
 
Line 31: Line 31:


===== (b) 72-hour quantitative fecal fat (Gold standard): =====
===== (b) 72-hour quantitative fecal fat (Gold standard): =====
* A quantitaive test that determines fetal fat excretion for over 24hrs.
* A quantitaive test that determines fecal fat excretion for over 24hrs.
* Fecal fat excretion of >7g/day is diagnostic of malabsorption.
* Fecal fat excretion of >7g/day is diagnostic of malabsorption.
* Patients with steatorrhea usually have an excretion of >10g of fat per day.
* Patients with steatorrhea usually have an excretion of >10g of fat per day.

Latest revision as of 13:20, 8 January 2018

Chronic pancreatitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Chronic pancreatitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Abdominal X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

American Pancreatic Association Practice Guidelines

APA Clinical Practice Guidelines for Chronic pancreatiits

Chronic pancreatitis laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chronic pancreatitis laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chronic pancreatitis laboratory findings

CDC on Chronic pancreatitis laboratory findings

Chronic pancreatitis laboratory findings in the news

Blogs on Chronic pancreatitis laboratory findings

Directions to Hospitals Treating Chronic pancreatitis

Risk calculators and risk factors for Chronic pancreatitis laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Iqra Qamar M.D.[2]

Overview

The diagnosis of chronic pancreatitis is typically based on tests on pancreatic structure and function. Serum amylase and lipase are usually normal but may be slightly elevated. Serum calcium and triglyceride levels may be elevated in hypertriglyceridemia induced pancreatitis. A secretin stimulation test is considered the gold standard functional test for diagnosis of chronic pancreatitis. Fecal tests may include sudan staining of feces, 72-hour quantitative fecal fat (Gold standard), and faecal elastase measurement (test of choice).

Laboratory Findings

  • The diagnosis of chronic pancreatitis is typically based on tests on pancreatic structure and function, as direct biopsy of the pancreas is considered excessively risky.
  • Serum amylase and lipase are usually normal but may be slightly elevated (neither diagnostic nor prognostic).
  • Serum bilirubin and alkaline phosphatase levels may be elevated in case of intra-pancreatic biliary duct obstruction.
  • Serum calcium and triglyceride levels may be elevated in hypertriglyceridemia induced pancreatitis.
  • The following lab tests are usually normal:
    • CBC
    • LFTs
    • Electrolytes
  • A secretin stimulation test is considered the gold standard functional test for diagnosis of chronic pancreatitis. The observation that bi-carbonate production is impaired early in chronic pancreatitis has led to the rationale of use of this test in early stages of disease (sensitivity of 95%).
  • Autoimmune pancreatitis can be diagnosed with elevated levels of:[1][2][3]

Fecal tests:

(a) Sudan staining of feces:
  • A non-specific, qualitative test that is no longer used for the diagnosis of steatorrhea
(b) 72-hour quantitative fecal fat (Gold standard):
  • A quantitaive test that determines fecal fat excretion for over 24hrs.
  • Fecal fat excretion of >7g/day is diagnostic of malabsorption.
  • Patients with steatorrhea usually have an excretion of >10g of fat per day.
(c) Faecal elastase measurement (Test of choice):
  • The most sensitive and specific test for pancreatic exocrine dysfunction.
  • It can be done with a single random stool sample.
  • The results are independent of pancreatic enzyme replacement therapy.
  • A value of less than 200 ug/g indicates pancreatic insufficiency.[4][5][6][7]

Pancreatic function tests:

(a) Direct/ Invasive tests:
  • Direct tests are used to assess pancreatic insufficiency in the early course of disease when patient has clinical symptoms but no radiology findings.
  • Direct tests involve pancreatic stimulation via meal or hormonal secretagogues and assessment of pancreatic secretions in the duodenal fluid.
  • Direct tests along with radiographic findings (pancreatic calcifications) are stll considered to be the gold standard for the diagnosis of chronic pancreatitis.[8][9][10][11]
  • The limitation of direct tests is that they are costly and cumbersome.[8][9][10][11]
  • Direct tests include:
    • Secretin stimulation test
    • Pancreozymin-secretin test
  • Secretin stimulation test is considered the gold standard functional test for diagnosis of chronic pancreatitis.
    • The observation that bi-carbonate production is impaired early in chronic pancreatitis has led to the rationale of use of this test in early stages of disease.
      • Sensitivity - 82%[12]
      • Specificity- 86%[12]
(b) Indirect/ Non-invasive tests:
  • Indirect tests are used to assess the complications of chronic pancreatitis.
  • Indirect tests include:
    • Faecal chymotrypsin, PABA-, pancreolauryl-
    • Faecal elastase test
  • Indirect tests are not sensitive to assess pancreatic insufficiency in the early course of disease.[11][13]

References

  1. Ghazale A, Chari ST, Smyrk TC, Levy MJ, Topazian MD, Takahashi N, Clain JE, Pearson RK, Pelaez-Luna M, Petersen BT, Vege SS, Farnell MB (2007). "Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer". Am. J. Gastroenterol. 102 (8): 1646–53. doi:10.1111/j.1572-0241.2007.01264.x. PMID 17555461.
  2. Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, Fukushima M, Nikaido T, Nakayama K, Usuda N, Kiyosawa K (2001). "High serum IgG4 concentrations in patients with sclerosing pancreatitis". N. Engl. J. Med. 344 (10): 732–8. doi:10.1056/NEJM200103083441005. PMID 11236777.
  3. Raina A, Krasinskas AM, Greer JB, Lamb J, Fink E, Moser AJ, Zeh HJ, Slivka A, Whitcomb DC (2008). "Serum immunoglobulin G fraction 4 levels in pancreatic cancer: elevations not associated with autoimmune pancreatitis". Arch. Pathol. Lab. Med. 132 (1): 48–53. doi:10.1043/1543-2165(2008)132[48:SIGFLI]2.0.CO;2. PMID 18181673.
  4. Freedman SD. "Clinical manifestations and diagnosis of chronic pancreatitis in adults". UpToDate.
  5. Keim V, Teich N, Moessner J (2003). "Clinical value of a new fecal elastase test for detection of chronic pancreatitis". Clin. Lab. 49 (5–6): 209–15. PMID 15285176.
  6. Walkowiak J, Herzig KH, Strzykala K, Przyslawski J, Krawczynski M (2002). "Fecal elastase-1 is superior to fecal chymotrypsin in the assessment of pancreatic involvement in cystic fibrosis". Pediatrics. 110 (1 Pt 1): e7. PMID 12093988.
  7. Borowitz D, Baker SS, Duffy L, Baker RD, Fitzpatrick L, Gyamfi J, Jarembek K (2004). "Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis". J. Pediatr. 145 (3): 322–6. doi:10.1016/j.jpeds.2004.04.049. PMID 15343184.
  8. 8.0 8.1 Boeck WG, Adler G, Gress TM (2001). "Pancreatic function tests: when to choose, what to use". Curr Gastroenterol Rep. 3 (2): 95–100. PMID 11276375.
  9. 9.0 9.1 Chowdhury RS, Forsmark CE (2003). "Review article: Pancreatic function testing". Aliment. Pharmacol. Ther. 17 (6): 733–50. PMID 12641496.
  10. 10.0 10.1 Siegmund E, Löhr JM, Schuff-Werner P (2004). "[The diagnostic validity of non-invasive pancreatic function tests--a meta-analysis]". Z Gastroenterol (in German). 42 (10): 1117–28. doi:10.1055/s-2004-813604. PMID 15508057.
  11. 11.0 11.1 11.2 Ammann RW (2006). "Diagnosis and management of chronic pancreatitis: current knowledge". Swiss Med Wkly. 136 (11–12): 166–74. doi:2006/11/smw-11182 Check |doi= value (help). PMID 16633964.
  12. 12.0 12.1 Ketwaroo G, Brown A, Young B, Kheraj R, Sawhney M, Mortele KJ, Najarian R, Tewani S, Dasilva D, Freedman S, Sheth S (2013). "Defining the accuracy of secretin pancreatic function testing in patients with suspected early chronic pancreatitis". Am. J. Gastroenterol. 108 (8): 1360–6. doi:10.1038/ajg.2013.148. PMC 5388854. PMID 23711627.
  13. Etemad B, Whitcomb DC (2001). "Chronic pancreatitis: diagnosis, classification, and new genetic developments". Gastroenterology. 120 (3): 682–707. PMID 11179244.


Template:WikiDoc Sources